This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pharma Stock Roundup: PFE COVID-19 Vaccine Final Analysis, FDA Updates & More
by Kinjel Shah
Pfizer (PFE) COVID-19 vaccine candidate proves to be 95% effective in final analysis. Sanofi (SNY), Lilly (LLY), Merck (MRK) & Glaxo (GSK) provide FDA updates.
Gilead (GILD) Reports Positive Top-Line Data on HIV Candidate
by Zacks Equity Research
Gilead (GILD) announces successful top-line results from a phase I/II study on its investigational, long-acting HIV-1 capsid inhibitor.
Major Indices Fall Despite Positive Coronavirus Vaccine Data
by Indrajit Bandyopadhyay
Stock market declines as Pfizer (PFE) /BioNtech's (BNTX) vaccine candidate, with efficacy rate of 95%, gets overshadowed by fresh coronavirus cases and no sign of new fiscal stimulus.
Glaxo (GSK) Candidate Gets Breakthrough Tag for HIV Prevention
by Zacks Equity Research
FDA grants breakthrough designation to Glaxo's (GSK) long-acting injectable cabotegravir to decrease the risk of HIV acquisition in at-risk populations.
Ternium, Virgin Galactic, Moderna, Pfizer and Johnson & Johnson highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Ternium, Virgin Galactic, Moderna, Pfizer and Johnson & Johnson highlighted as Zacks Bull and Bear of the Day
3 Stocks to Win Big as Race for Coronavirus Vaccine Heats Up
by Tirthankar Chakraborty
Coronavirus vaccine race is now at its peak following Moderna's (MRNA) 94.5% effective vaccine in Phase 3 trials. Pfizer (PFE) also bragged about the effectiveness of its vaccine to be more than 90%.
J&J (JNJ) Expands BARDA Deal for COVID-19 Vaccine Development
by Zacks Equity Research
J&J's (JNJ) ENSEMBLE study on its COVID-19 vaccine candidate is expected to enroll 60,000 adult participants.
Vaccine Hopes Push Markets To Frothy Levels: Stocks To Watch
by Daniel Laboe
There is now a more defined light at the end of this pandemic tunnel. Still, we are not out of the woods yet.
Pharma Stock Roundup: PFE Coronavirus Data, FDA Emergency Tag for LLY COVID-19 Drug
by Kinjel Shah
Eli Lilly (LLY) and Pfizer (PFE) provide updates on their coronavirus vaccine/antibody candidates.
J&J (JNJ) Seeks Label Expansion of Darzalex Faspro Combination
by Zacks Equity Research
J&J (JNJ) files regulatory application in the United States and Europe seeking label expansion of Darzalex Faspro in combination with pomalidomide and dexamethasone for treating multiple myeloma.
Johnson & Johnson (JNJ) Down 0.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AstraZeneca's (AZN) Calquence Fails in Coronavirus Study
by Zacks Equity Research
AstraZeneca's (AZN) BTK inhibitor drug Calquence fails to achieve the main goal in the phase II CALAVI studies for patients hospitalized with respiratory symptoms of COVID-19.
Pfizer (PFE) to Supply 200M Doses of COVID-19 Vaccine to EU
by Zacks Equity Research
Pfizer (PFE) and BioNTech sign a supply deal with the European Union for up to 300 million doses of their coronavirus vaccine.
The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna, AstraZeneca and Johnson & Johnson
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna, AstraZeneca and Johnson & Johnson
Pfizer COVID-19 Vaccine Data Raises Hopes for Industry, Economy
by Kinjel Shah
Pfizer (PFE)/BioNTech's (BNTX) COVID-19 vaccine candidate proves to be 90% effective in phase III.
Theravance (TBPH) Drops on Q3 Earnings Miss, Revenues In Line
by Zacks Equity Research
Theravance (TBPH) falls more than 13% as it reports wider-than-expected loss for the third quarter of 2020. Revenues meet estimates.
Emergent (EBS) Beats on Q3 Earnings, Tapers '20 Sales View
by Zacks Equity Research
Emergent (EBS) beats on earnings in Q3 while revenues miss estimates. Total product sales fall year over year and the company tightens its revenue guidance. Stock slides in after-hours trading.
Should iShares Morningstar LargeCap Value ETF (JKF) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JKF
AstraZeneca (AZN) Q3 Earnings Miss Estimates, Sales Beat
by Zacks Equity Research
AstraZeneca (AZN) lags Q3 earnings estimates and surpasses the same for sales. It maintains its financial outlook for the year.
The Zacks Analyst Blog Highlights: Google, Johnson & Johnson, Union Pacific Corp, Eli Lilly, Charter Communications and Anheuser-Busch InBev
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Google, Johnson & Johnson, Union Pacific Corp, Eli Lilly, Charter Communications and Anheuser-Busch InBev
Vaxart (VXRT) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
During Vaxart's (VXRT) impending third-quarter conference call, investors will keep tabs of its progress with its oral COVID-19 vaccine candidate VXA-CoV2-1.
Bayer's (BAYRY) Q3 Earnings & Sales Miss Estimates, Down Y/Y
by Zacks Equity Research
Bayer (BAYRY) misses both earnings and sales estimates in the third quarter of 2020.
Halozyme (HALO) Q3 Earnings Top, 2020 View Up, Stock Rises
by Zacks Equity Research
Halozyme (HALO) reports better-than-expected third-quarter results. The company raises outlook for the year anticipating higher royalties.
Should iShares Russell Top 200 Value ETF (IWX) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWX
Top Research Reports for Alphabet, Johnson & Johnson & Union Pacific
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Alphabet (GOOGL), Johnson & Johnson (JNJ) and Union Pacific (UNP).